v3.26.1
Segment Information
 9 Months Ended 12 Months Ended
Mar. 31, 2026
Jun. 30, 2025
Segment Information [Abstract]    
SEGMENT INFORMATION
9.
SEGMENT INFORMATION
The Company reports segment information based on the management approach, which designates the internal reporting used by the Chief Operating Decision Maker (“CODM”), the Company’s
Chief Executive Officer
and the senior management team, for making decisions and assessing performance as the source of the Company’s reportable segment. The Company has determined its reportable segment to be the Pharma segment based on the information used by the CODM. Other than cash, cash equivalents and short-term investments (“Unrestricted cash”) balances, the CODM does not regularly review asset information by reportable segment and, therefore, the Company does not report asset information by reportable segment.
 
The following table presents information about the Company’s reportable segment for the three and nine months ended March 31, 2026 and 2025:
 
    
For the Three Months Ended
March 31,
     
For the Nine Months Ended
March 31,
  
    
2026
      2025     
2026
      2025  
    
$
      $     
$
      $  
Operating Expenses
            
Research and development
   
 
1,022,630
 
      425,370     
 
2,222,732
 
      2,243,948  
General and administrative
   
 
1,742,016
 
      1,584,393     
 
4,304,323
 
      4,155,493  
Amortization and depreciation
   
 
51,707
 
      51,706     
 
156,912
 
      158,289  
Foreign exchange loss (gain)
   
 
23,168
 
      22,165     
 
62,026
 
      50,608  
  
 
 
     
 
 
     
 
 
     
 
 
  
Total operating expenses
   
 
2,839,521
 
      2,083,634     
 
6,745,993
 
      6,608,338  
Other Income (Expense)
            
Interest and other income
   
 
47,770
 
      16,565     
 
215,914
 
      104,195  
Finance expense
   
 
— 
 
      —      
 
— 
 
      (351,549 ) 
  
 
 
     
 
 
     
 
 
     
 
 
  
Net loss from continuing operations before taxes
   
 
(2,791,751
) 
      (2,067,069 )    
 
(6,530,079
) 
      (6,855,692 ) 
Income tax expense
   
 
— 
 
      —      
 
— 
 
      —   
  
 
 
     
 
 
     
 
 
     
 
 
  
Net loss from continuing operations
   
 
(2,791,751
) 
      (2,067,069 )    
 
(6,530,079
) 
      (6,855,692 ) 
  
 
 
     
 
 
     
 
 
     
 
 
  
11.
SEGMENT INFORMATION
The Company reports segment information based on the management approach, which designates the internal reporting used by the Chief Operating Decision Maker (“CODM”), the Company’s
Chief Executive Officer
and the senior management team, for making decisions and assessing performance as the source of the Company’s reportable segments. The CODM allocates resources and assesses the performance of each operating segment based on potential licensing opportunities, historical and potential future product sales, operating expenses, and operating income (loss) before interest and taxes. The Company has determined its reportable segments to be ‘InMed Pharma’ and ‘BayMedica Commercial’ based on the information used by the CODM. Other than cash, cash equivalents and short-term investments (“Unrestricted cash”) balances,
 
the CODM does not regularly review asset information by reportable segment and, therefore, the Company does not report asset information by reportable segment.
The InMed Pharma segment is largely organized around the research and development of small molecule pharmaceuticals drug candidates and the BayMedica Commercial segment is largely organized around manufacturing technologies to produce and commercialize bulk rare cannabinoids for sale as ingredients in the health and wellness industry. Total assets held in the ‘InMed Pharma’ segment as of June 30, 2025 and 2024 were $13.7 million and $9.2 million, respectively. Total assets as of June 30, 2025 and 2024, held in the BayMedica Commercial segment were $1.9 million and $2.6 million, respectively.
The following table presents information about the Company’s reportable segments for the years ended June 30, 2025 and 2024:
 
    Year Ended June 30,  
    2025     2024  
    InMed     BayMedica    
Total
     InMed     BayMedica    
Total
  
   
$
    
$
    
$
    
$
    
$
    
$
  
Sales
      —       4,942,633    
 
4,942,633
 
      —       4,597,730    
 
4,597,730
 
Cost of sales
      —       (3,236,047 )   
 
(3,236,047
) 
      —       (3,496,817 )   
 
(3,496,817
) 
Operating expenses
     (8,474,641 )      (1,178,411 )   
 
(9,653,052
) 
     (8,400,411 )      (896,853 )   
 
(9,297,264
) 
Other income (expense)
     155,882        —    
 
155,882
 
     532,782       (4,881 )   
 
527,901
 
Finance Expense
     (371,549 )       —    
 
(371,549
) 
      —        —    
 
 —
 
(Loss) income before income taxes
     (8,690,308 )      528,175    
 
(8,162,133
) 
     (7,867,629 )      199,179    
 
(7,668,450
) 
 
 
 
    
 
 
    
 
 
    
 
 
    
 
 
    
 
 
  
Unrestricted cash
     10,684,376       391,495    
 
11,075,871
 
     5,669,113       902,497    
 
6,571,610